A recent study demonstrated that SGLT2 inhibitors were also associated with lower rate of cardiac events among patients with cancer and DM in patients who were treated with anthracyclines, however, randomized trials testing the effect of SGLT2 inhibitors on cardiac outcomes in patients treated with anthracyclines are still required (136). This evidence concerns the gene SLC5A2 and cancer.